Sunday 18 October 2026
Export NRXP’s income statement to Excel — free account
NRx Pharmaceuticals, Inc.
NRXP Healthcare Biotechnology
NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million. In the quarter to June 2026, EPS grew 55.1% and free cash flow fell 142.6%, each against the same quarter a year earlier.
2.60
0.11
−4.06%
Follow NRXP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 45.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(25.38) | (15.62) | (16.03) | (17.35) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 0.00 | 0.00 | 39.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.50) | (4.63) | (5.17) | (6.71) | |
EV/FCF |
(6.50) | (4.62) | (5.17) | (6.42) | |
Quick Ratio |
0.26 | 0.28 | 0.27 | 0.79 | |
Current Ratio |
0.29 | 0.31 | 0.29 | 0.86 | |
Net Debt/EBITDA |
(0.71) | 1.72 | 1.47 | 4.15 | |
Debt/Assets |
67.09% | 0.00% | 0.00% | 1.21% | |
Debt/Equity |
(0.39) | 0.00 | 0.00 | (2.42) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.17 | |
Operating CF/Net income |
0.49 | (10.29) | 3.00 | 0.54 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (5.18) | |
Interest Coverage |
— | — | (20.35) | (27.10) | |
Research and Development Expense of Revenue |
590.50% | 56.66% | 122.57% | 192.19% | |
Selling, General and Administrative Expense of Revenue |
1,160.33% | 464.60% | 357.02% | 430.97% | |
Intangible Assets out of Total Assets |
0.16 | 0.21 | 0.22 | 0.08 | |
Share Based Compensation of Revenue |
28.10% | 8.24% | 14.14% | 12.62% | |
Graham Net Nets |
(0.39) | (0.34) | (0.27) | (0.03) | |
Graham Number |
7.83 | 4.83 | 3.24 | 0.24 | |
Earnings Yield |
(71.21%) | (51.29%) | (51.17%) | (13.45%) | |
Free Cash Flow Yield |
(17.04%) | (24.34%) | (21.68%) | (13.42%) | |
Revenue per Share |
0.01 | 0.05 | 0.03 | 0.03 | |
Operating CF per Share |
(0.13) | (0.17) | (0.13) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.13) | (0.17) | (0.13) | (0.26) | |
Cash per Share |
0.32 | 0.36 | 0.21 | 0.71 | |
Shareholders Equity per Share |
(1.16) | (0.74) | (0.43) | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.16) | (0.74) | (0.43) | 0.00 | |
Free Cash Flow |
(2.89) | (3.71) | (4.29) | (9.77) | |
Working Capital |
(28.65) | (19.69) | (17.81) | (4.72) | |
Capital Expenditures |
— | — | — | (0.90) | |
Net Current Asset Value |
(28.80) | (20.00) | (18.36) | (5.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.81 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.94 | 0.08 | 0.09 | 0.11 | |
Average Payables |
4.56 | 4.20 | 4.36 | 3.39 | |
Average Assets |
9.73 | 8.30 | 9.75 | 19.50 | |
Average Common Equity |
(22.29) | (19.58) | (19.49) | (17.89) |
Columns are period end dates